CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired Distributed Bio, Inc., a transaction completed in December 2020.
Distributed Bio, Inc. operates in Discovery and Safety Assessment (DSA) — antibody discovery, is based in United States (San Francisco / South San Francisco, California). Distributed Bio was a next-generation antibody discovery company with technologies specializing in enhancing the probability of success for delivering high-quality, readily formattable antibody fragments to support antibody and cell and gene therapy candidates.
The acquisition of Distributed Bio expands our capabilities with an innovative, large-molecule discovery platform, and creates an integrated, end-to-end platform for therapeutic antibody and cell and gene therapy discovery and development.
DSA segment, large-molecule / antibody discovery
In December 2020, we acquired Distributed Bio, a next-generation antibody discovery company. The acquisition expands Charles River's scientific capabilities with an innovative, large-molecule discovery platform. The transaction combines Distributed Bio's antibody libraries and immuno-engineering platform with our extensive drug discovery and non-clinical development expertise.Charles River FY2020 10-K, Business / Item 1 description
Advisory firms were not disclosed for this transaction.